Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

Published:2017-09-06 Issue:11 Volume:72 Page:3131-3140
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Dorlo Thomas P C¹²^ORCID,Kip Anke E²,Younis Brima M³,Ellis Sally J⁴,Alves Fabiana⁴,Beijnen Jos. H²,Njenga Simon⁵,Kirigi George⁵,Hailu Asrat⁶,Olobo Joseph⁷,Musa Ahmed M³,Balasegaram Manica⁴,Wasunna Monique⁸,Karlsson Mats O¹,Khalil Eltahir A G³

Affiliation:

1. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

2. Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, the Netherlands

3. Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan

4. Drugs for Neglected Diseases initiative, Geneva, Switzerland

5. Kenya Medical Research Institute, Nairobi, Kenya

6. Addis Ababa University, Addis Ababa, Ethiopia

7. Makerere University, Kampala, Uganda

8. Drugs for Neglected Diseases initiative, Nairobi, Kenya

Funder

DFID

Dutch Ministry of Foreign Affairs

Federal Ministry of Education and Research

BMBF

Swiss Agency for Development and Cooperation

Netherlands Organisation for Scientific Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/72/11/3131/24332197/dkx283.pdf

Reference29 articles.

1. Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia;Harhay;Am J Trop Med Hyg,2011

2. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India;Boelaert;Trop Med Int Health,2009

3. Leishmaniasis worldwide and global estimates of its incidence;Alvar;PLoS One,2012

4. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance;Rijal;Clin Infect Dis,2013

5. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis;Dorlo;J Antimicrob Chemother,2012

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa;The Journal of Infectious Diseases;2024-08-21

2. Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach;Antimicrobial Agents and Chemotherapy;2024-07-09

3. Pharmacokinetics, Dose-Proportionality, and Tolerability of Intravenous Tanespimycin (17-AAG) in Single and Multiple Doses in Dogs: A Potential Novel Treatment for Canine Visceral Leishmaniasis;Pharmaceuticals;2024-06-11

4. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia;Journal of Antimicrobial Chemotherapy;2024-05-10

5. Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model;PLOS Neglected Tropical Diseases;2024-04-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3